home / stock / cltef / cltef short
Short Information | Calliditas Therapeutics AB - Class B (OTCMKTS:CLTEF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 7,500 |
Total Actual Volume | 8,700 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 13 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 375 |
Average Short Percentage | 64.14% |
Is there a CLTEF Short Squeeze or Breakout about to happen?
See the CLTEF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
12-17-2021 | $12.08 | $12.08 | $12.08 | $12.08 | 300 | 300 | 100% |
12-15-2021 | $8.18 | $9.92 | $9.92 | $8.18 | 7,000 | 5,800 | 82.86% |
06-07-2021 | $14.12 | $14.12 | $14.12 | $14.12 | 100 | 100 | 100% |
06-04-2021 | $14.37 | $14.37 | $14.37 | $14.37 | 300 | 300 | 100% |
05-28-2021 | $14.86 | $14.86 | $14.86 | $14.86 | 100 | 100 | 100% |
05-26-2021 | $14.85 | $14.85 | $14.85 | $14.85 | 100 | 100 | 100% |
05-24-2021 | $14.92 | $15 | $15 | $14.92 | 200 | 200 | 100% |
05-11-2021 | $13.54 | $13.54 | $13.54 | $13.54 | 100 | 100 | 100% |
04-23-2021 | $13.7 | $13.7 | $13.7 | $13.7 | 100 | 100 | 100% |
04-15-2021 | $13.62 | $13.62 | $13.62 | $13.62 | 100 | 100 | 100% |
04-13-2021 | $13.49 | $13.49 | $13.49 | $13.49 | 100 | 100 | 100% |
04-09-2021 | $13.78 | $13.78 | $13.78 | $13.78 | 100 | 100 | 100% |
03-25-2021 | $13.95 | $13.95 | $13.95 | $13.95 | 100 | 100 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB - Class B Company Name:
CLTEF Stock Symbol:
OTCMKTS Market:
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...
Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...
Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...